Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome

Trial Profile

Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Jun 2015 According to a SymBio Pharmaceuticals media release, the company completion of this phase I study for oral rigosertib (SyB C-1101).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top